Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24069085 | 1.00 | POLB (0.48) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL30209757 | 1.00 | POLB (0.48) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL24069920 | 0.83 | ALDH1A1 (0.45) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL24069136 | 0.82 | POLB (0.48) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL30209728 | 0.82 | POLB (0.48) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL24070475 | 0.78 | ALDH1A1 (0.47) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL30369632 | 0.78 | ALDH1A1 (0.47) | POLBIDO1LMNAHTTPKM | |
| SCHEMBL15162220 | 0.73 | HTT (0.53) | POLBLMNAHTTPKMKMT2A | |
| SCHEMBL15162764 | 0.73 | HTT (0.53) | POLBLMNAHTTPKMKMT2A | |
| SCHEMBL24070484 | 0.72 | KMT2A (0.46) | POLBHTTKMT2AGAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4157821-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115867535-A | Substituted benzamides as modulators of TREX1 | 星座制药公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | TREH, BRIX1, GBA1 | POLB 2629/4885IDO1 2661/4885LMNA 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.